Estimation of the neurovirulence of poliovirus by non-radioisotope molecular analysis to quantify genomic changes

Biologicals

Volumn 26, Issue 4, 1998, Pages 289-297

  Horie, Hitoshi ^a   Tano, Yoshio ^a   Doi, Yutaka ^a   Hashizume, So ^a  

^a Japan Poliomyelitis Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; RADIOISOTOPE; RESTRICTION ENDONUCLEASE;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; DRUG SAFETY; ENZYME ANALYSIS; GENE MUTATION; GENETIC STABILITY; MONKEY; MUTATION RATE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; POLIOMYELITIS VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 0032452506     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1998.0159     Document Type: Article

References (27)

1. 1. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973; 1: 115-118.
2. 2. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151: 420-436.
3. 3. WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine: results of a ten-year enquiry. Bull WHO 1982; 60: 231-242.
4. 4. Nkowane BM, Wassilak SGF, Orenstein WA et al. Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. JAMA 1987; 257: 1335-1340.
5. 5. Friedrich F. Genomic modifications in Sabin Vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virologica 1996; 40: 157-170.
6. 6. Holland J, Spindler K, Horodyski F et al. Rapid evolution of RNA genomes. Science 1982; 215: 1577-1585.
7. 7. Ward CD, Stockes MAM, Flanegan JB. Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol 1988; 62: 558-562.
8. 8. WHO Expert Committee on Biological Standardization. Requirements for poliomyelitis vaccine. WHO Techn Rep Ser 1990; 800: 30-65.
9. 9. Kawamura N, Kohara M, Abe S et al. Determinants in the 5′ non coding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 1989; 63: 1302-1309.
10. 10. Christodoulou C, Colber-Garapin F, Macadam A et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 1990; 64: 4922-4929.
11. 11. Horie H, Koike S, Kurata T et al. Transgenic mice carrying the human poliovirus receptor: new animal model for study of poliovirus neurovirulence. J Virol 1994; 68: 681-688.
12. 12. Pollard SR, Dunn G, Cammack N et al. Nucleotide sequence of a neurovirulent variant of the Type 2 oral poliovirus vaccine. J Virol 1989; 63: 4949-4951.
13. 13. Macadam AJ, Pollard SR, Ferguson G et al. The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 1991; 181: 451-458.
14. 14. Evans DMA, Dunn G, Minor PD et al. Increased neurovirulence associated with a single nucleotide change in a non-coding region of the Sabin type 3 poliovaccine genome. Nature 1985; 314: 548-550.
15. 15. Westrop GD, Wareham KA, Davis DMA et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 1989; 63: 1338-1344.
16. 16. Chumakov KM, Powers LB, Noonan KE et al. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 1991; 88: 199-203.
17. 17. Chumakov KM, Norwood LP, Parker ML et al. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol 1992; 66: 966-970.
18. 18. Chumakov KM, Norwood LP, Parker ML et al. Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Dev Biol Stand 1993; 78: 79-89.
19. 19. Rezapkin GV, Chumakov KM, Lu Z et al. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 1994; 202: 370-378.
20. 20. Taffs RE, Chumakov KM, Rezapkin GV et al. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 1995; 209: 366-373.
21. 21. Rezapkin GV, Norwood LP, Taffs RE et al. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control. Virology 1995; 211: 377-384.
22. 22. Wood DJ. New approaches to oral poliovirus vaccine neurovirulence tests: transgenic mice susceptible to poliovirus and molecular analysis of poliovirus. Vaccine 1997; 15: 341-345.
23. 23. Pilipenko EV, Blinov VM, Romanova LI et al. Conserved structural domains in the 5′-untranslated region of Picornaviral genomes: An analysis of the segment controlling translation and neurovirulence. Virology 1989; 168: 201-209.
24. 24. Skinner MA, Racaniello VR, Dunn G et al. New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol 1989; 207: 379-392.
25. 25. Muzychenko AR, Lipskaya GY, Maslova SV et al. Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passages: Structural and functional implications. Virus Res 1991; 21: 111-122.
26. 26. Chanock RM. Reminiscences of Albert Sabin and his successful strategy for the development of the live oral poliovirus vaccine. In: (Brown F, Norrby E. Burton D. and Mekalanos J. eds), Vaccines 96, Cold Spring Harbor, New York, 1996; pp. 335-348.
27. 27. Minor PD. Poliovirus biology. Structure 1996; 4: 775-778.